Floatz logo

Allogeneic Bone Marrow-Derived Mscs

Platinum-Resistant Ovarian Carcinoma

Roswell Park Cancer InstituteCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Platinum-Resistant Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Durvalumab
AGO Research GmbH
Phase 2BB
Guadecitabine
National Cancer Institute (NCI)
Phase 2BB
Zofran
Mayo Clinic
Phase 2B
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Mayo Clinic
Phase 2B
Irinotecan Sucrosofate
Northwestern University
Phase 2B

View all 17 →

Same molecule, other indications

Allogeneic Bone Marrow-Derived Mscs is also rated in:

lumbar disk degenerative disorderDormant
CCC
Indicative ·
54 / 100
View asset →
bone marrow failure syndromeDormant
CCC
Indicative ·
48 / 100
View asset →
bipolar depressionDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →